Table 2. Patent ductus arteriosus (PDA) treatment strategies according to the gestational age group.
| Treatment | Gestational age at birth (weeks) | Total (n = 2,254) |
|||
|---|---|---|---|---|---|
| <24 (n=113) |
24-27 (n=766) |
28-31 (n=1,043) |
≥32 (n=332) |
||
| No PDA group | 28 (24.8%) |
223 (29.1%) |
664 (63.7%) |
291 (87.7%) |
1,206 (53.5%) |
| PDA group | 85 (75.2%) |
543 (70.9%) |
379 (36.3%) |
41 (12.3%) |
1,048 (46.5%) |
| PT group | 11 (9.7%) |
31 (4.0%) |
24 (2.3%) |
3 (0.9%) |
69 (3.1%) |
| PST group | 10 (8.8%) |
107 (14.0%) |
84 (8.1%) |
11 (3.3%) |
212 (9.4%) |
| ST group | 35 (31.0%) |
307 (40.1%) |
233 (22.3%) |
21 (6.3%) |
596 (26.4%) |
| CT group | 29 (25.7%) |
98 (12.8%) |
38 (3.6%) |
6 (1.8%) |
171 (7.6%) |
*In multinomial logit model, the odds ratio (OR) of the ratio of CT vs. PST was 5.3 [95% confidence interval (CI) 1.56-18.18] and OR of the ratio of CT vs. ST was 2.9 (95% CI 1.03-8.13) in GA <24 weeks group when compared with GA≥32 weeks group. P<0.001 in 4 PDA treatment subgroups according to GA by chi-square test. PT, prophylactic treatment; PST, pre-symptomatic treatment; ST, symptomatic treatment; CT, conservative treatment; PDA, patent ductus arteriosus; GA, gestational age; OR, odds ratio.